Malignant mesothelioma is a rare malignancy of the body cavities with dismal prognosis. It has been a diagnostic dilemma for years with many clinical and pathological mimics. Discovery of a reliable tumour marker will
in the gene encoding for the mesothelin protein, leading to release of the protein into the blood stream while others suggest a proteolytic cleavage and release of the soluble Malignant mesothelioma is a highly aggressive tumour with fragment of the protein into the an incidence progressively increasing with time. The tumour circulation. originates from cells lining the serosal cavities, the most common location being the pleura. It also arises from the Robinson et al, [1] in his study on peritoneum, pericardium and tunica vaginalis. Asbestos mesothelin family of proteins, found exposure is the prime factor implicated in the pathogenesis that patients with malignant of the tumour but few cases have also been associated with mesothelioma had a higher levels of exposure to ionising radiation and viral infections. Asbestos serum mesothelin related peptide occurs predominantly in two forms, the serpentines and the (SMR) than the healthy controls (both amphiboles, latter implicated in causation of the disease more asbestos exposed and non exposed). frequently, owing to its more rigid structure, which causes Patients with lung adenocarcinoma, considerable damage to the mesothelial cells. metastatic pleural tumours and non mesotheliomatous pleural effusions Malignant mesothelioma has got a grim prognosis, did not show raised levels. The data attributable to the late detection of the disease. Moreover the established 84% sensitivity and 100% screening of individuals exposed to asbestos is very difficult specificity of serum SMR assay in the proven.
because of the extremely long latency period, ranging from diagnosis of malignant mesothelioma. 10 to 30 years. The diagnosis of malignant mesothelioma is
The efficacy of serum SMR assay was based on combination of clinical history, radiological further substantiated by Scherpereel appearances and histology. Despite all these modalities, et al.
[2] Raised levels of SMR were diagnosis remains a challenging task to medical profession found in patients with malignant as symptoms, imaging and the histological features often mesothelioma compared to patients mimics other pathologies. Fair numbers of tumour markers with metastatic tumours to the pleura are under research with few emerging as promising ones. A and benign pleural lesions following reliable tumour marker will simplify and fasten the process exposure to asbestos. SMR assay was of diagnosing malignant mesothelioma, enabling a larger also proven to be of value in further number of patients to be diagnosed in the initial stages and studies [3] and levels were found to undertake more successful treatment options.
mirror the tumour bulk and thus can Rao P, et al.: Serum tumour markers in malignant mesothelioma be used for monitoring the course of the disease and to screen patients who are at risk. The levels of SMR may correlate with the histological subtype of the tumour with the highest levels found in the epithelioid subtype.
[2] Hassan et al in his study on patients with mesothelioma demonstrated a decrease in the levels of serum mesothelin after surgical treatment suggesting that it can be used to monitor the treatment response.
[4]
Apart from the usefulness of serum SMR assay in diagnosing mesothelioma, it has also been found to be a useful marker to follow patients who are at risk. People who had an asbestos
The fact that the levels were significantly raised in patients with malignant mesothelioma compared to healthy people with a history of asbestos exposure can be of immense value in screening of people who are at risk. As asbestos exposure is also implicated in causation of malignancies other than malignant mesothelioma (gastrointestinal, laryngeal and urinary), asbestos workers with raised osteopontin levels and no evidence of malignant mesothelioma should be investigated for other malignancies.
SERUM PDGF
exposure history and significantly raised SMR levels were PDGF is a protein secreted from the alpha granules of the followed and found to develop malignant mesothelioma in due platelets and mesenchymal cells. It regulates cell division course of time. These patients were found to have raised levels and growth and also has a role in migration and angiogenesis. one to 4 years before the symptom development.
[5] Hence a It is overexpressed in many inflammatory conditions, cautious approach in people showing a raised level is atherosclerosis and malignancies. It exists as a diamer with advisable as this may signify a hidden focus of malignancy the isoforms AA, AB and BB and binds to the tyrosine kinase not detectable by routine methods.
[2] It has also been family of receptors and signals tumour cell and stroma suggested by workers that fluctuations in the serum SMR proliferation through an autocrine or paracrine mode of levels over time may also point towards a developing action. malignant mesothelioma and can be a very useful approach to follow patients with a history of asbestos exposure.
[1] Thus The AA isoform is secreted by the fibroblasts, osteoblasts it can be said that it would be a safer approach to investigate and astrocytes. Macrophages and thyroid carcinoma cells at risk people with a raised SMR levels, with more aggressive secrete predominantly the BB isoform. Neurons, renal techniques to rule out a developing malignancy or a very small mesangial cells and mesothelial cells secrete the PDGF-AB focus of already developed malignancy, which can definitely isoform. add a ray of light to the existing prognosis of patients with malignant mesothelioma.
PDGF AB was found to be significantly higher in patients with mesothelioma compared to their healthy controls (both OSTEOPONTIN asbestos exposed and non exposed).
[7] However the levels in patients with malignant mesothelioma were not significantly Osteopontin also known as bone sialoprotein is a glycoprotein different from patients with non small cell lung carcinomas. considered to be a multifunctional cytokine found in the The levels showed a correlation with the histological subtype, osseous tissues, brain, kidney, chondrocytes and many other higher levels seen in epithelioid subtype. A significant tissues. It is overexpressed in a variety of cancers including correlation was also found between the platelet counts and malignant mesothelioma.
serum PDGF levels, implicating that a high platelet count at diagnosis may be a negative prognostic factor. Studies reveal that serum osteopontin levels were significantly higher in patients with malignant mesothelioma Serum PDGF levels can be used as marker to assess the compared to healthy controls with a history of asbestos exposure.
[6] However there was no significant difference in the levels of osteopontin among patients with different stages of disease signifying that it did not correlate well with the bulk of the disease. The levels also did not differ in different histological subtypes of the disease. Osteopontin levels have also been found to be elevated in patients with lung, ovarian, colorectal, gastric and pancreatic carcinomas, which can be a drawback to use this marker as a diagnostic marker independently, although it can be of value when used in combination with the existing diagnostic modalities owing to the fact that the duration of the disease and extent of radiological abnormalities correlated well with the levels of osteopontin.
[6] prognosis in patients diagnosed with malignant mesothelioma.
SERUM HYALURONAN
Hyaluronan is a glycosaminoglycan distributed widely in the body. It is found in the synovial fluid, connective tissue and vitreous humour of the eye. It is an important constituent of extra cellular matrix and functions in lubrication, cell growth and movement. ) .
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progression of the disease.
[8] The literature reports the sensitivity and specificity of serum hyalouronan to be 65% and 85% respectively as an indicator of disease progression.
[9]
However, the correlation of the serum levels to pleural fluid levels is still under speculation, with few studies reporting a positive correlation and few reporting the contrary.
Patients undergoing an increase in tumour volume manifest increased levels of hyalouronan in the serum while patients who respond to treatment favourably shows a declining trend in the values.
[9] All the more patients with highest levels at initial diagnosis seemed to have the shortest survival.
[10] The mean concentration of serum hyalouronan in malignant Its role in malignant mesothelioma has been investigated in few studies. It was found to be a useful marker in predicting disease progression and survival. [16] The values of TPA correlated well with the levels of CYFRA 21 [17] and in fact were more sensitive than CYFRA 21 in predicting the disease progression.
[18] It has also been helpful in indicating the response to chemotherapy.
CA-125 CA125 belongs to the carbohydrate antigen group of tumour markers and is frequently elevated in ovarian cancers. Elevated levels may also be seen in cancers of breast, endometrium, lung and in a few benign conditions like endometriosis. mesothelioma was five to ten times higher than that of normal Its significance in malignant mesothelioma of the peritoneum still needs to be studied in detail. It can be helpful in the A cautious approach is advisable in interpreting the levels of diagnosis in combination with the computed tomographic serum hyalouronan as raised levels are also seen in patients appearances [19] and also in follow up of patients undergoing with liver cirrhosis and chronic inflammatory conditions [12] chemotherapy as the serum levels reflect the tumour and the levels may remain normal in small sized tumours.
response.
[20]
FIBRONECTIN

CYFRA 21 is a soluble cytokeratin 19 fragment and can be
Fibronectin is a high molecular weight glycoprotein, which used as a tumour marker in many cancers. As the mesothelial binds to receptors known as integrins. It is involved in the cells express cytokeratin 19 in a very high concentration, the process of wound healing, embryogenesis and blood clotting. marker may be of use in the evaluation of the disease. Its It exists in 2 forms, an insoluble form found in extracellular value in the initial diagnosis may be limited by its wide spread matrix and a soluble form found in the plasma. expression in many cells. However levels of CYFRA 21 in concert with a low level of CEA may hint the diagnosis of Diagnostic accuracy of fibronectin in ascitic fluid was nearly malignant mesothelioma, while the reverse point towards an
100% for values more than 110 micrograms/ml in predicting adenocarcinoma of the lung.
malignancy. [21] Its levels in the urine have been found to be useful in prostate and urinary bladder cancers. Its role as a observed a significantly higher level of tumour marker in malignant mesothelioma has been CYFRA 21 in the serum of patients with malignant investigated by Emri et al. [22] The levels of fibronectin in the mesothelioma in comparison to patients with any benign pleural fluid and the plasma were elevated in patients with pulmonary disease. However, the difference in the levels malignant mesothelioma but were not statistically significant between patients with malignant mesothelioma and lung in comparison to tuberculous and carcinoma was not statistically significant. It can serve as a mesotheliomatous effusions. Thus measurement of serum marker for follow up of patients with established malignant fibronectin may not add much to the existing diagnostic aids. mesothelioma as it is found to have a significant prognostic controls.
[11]
CYFRA 21-1
Paganuzzi et al [13] other nonvalue for survival. [14] The sensitivity of serum CYFRA 21 levels for the diagnosis of malignant pleural mesothelioma has been stated to be 40% in the literature and the change in concentrations of the marker reflected the change in tumour burden. [15] 
TISSUE POLYPEPTIDE ANTIGEN
Tissue polypeptide antigen is a growth and proliferative cell marker. It is a polypeptide composed of cytokeratin 8, 18 and 19. It is found to be elevated in many cancers including squamous cell carcinoma of the head and neck region, salivary gland neoplasms, thyroid cancer and bladder cancers.
OTHERS
Few case reports have been published stating the paraneoplastic behaviour of the tumour. G-CSF, [23, 24] HCG [25] was found to be secreted by few of the tumours, manifesting as raised leukocyte levels and bilateral gynecomastia respectively. Rao P, et al.: Serum tumour markers in malignant mesothelioma certainly add to the existing diagnostic modalities, but further studies are required to substantiate the role of these tumour markers as an independent biomarker in the evaluation of MM. There are no established screening programmes, but these tumour markers may emerge as a cost effective screening tool in the near future, thereby reducing the disease morbidity.
CONCLUSION
